MyoKardia seeks accelerated development for heart drug

MyoKardia seeks accelerated development for heart drug

Dive Brief: Topline data from MyoKardia’s Phase 2 PIONEER-HCM study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) has shown enough benefit to encourage MyoKardia to seek a regulatory ok to start a pivotal study later this year....

Pin It on Pinterest